Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Safety Concerns Will Increase FDA-Industry Interactions, Schering Says

Executive Summary

Schering-Plough predicts that increased attention on drug safety issues will drive greater interactions with FDA

You may also be interested in...

Schering-Plough names pharmacovigilance head

Jean-Louis Saillot was appointed Schering-Plough VP-Global Pharmacovigilance effective Jan. 20; he previously held the position on an interim basis. Saillot is responsible for global product safety surveillance, aggregate safety reporting, pharmacoepidemiology and clinical risk management. He will report to Schering-Plough Research Institute President Cecil Pickett...

FDA Drug Safety Website Under Development As One Response To Concerns

FDA is understood to be developing a drug safety website as part of an initiative to address concerns about post-marketing surveillance

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts